期刊
CIRCULATION
卷 134, 期 23, 页码 1881-1906出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCULATIONAHA.116.023952
关键词
aspirin; percutaneous coronary intervention; platelet aggregation inhibitors; purinergic P2Y receptor antagonists; secondary prevention
资金
- European Association of Percutaneous Cardiovascular Intervention (EAPCI)
- Cardiopath PhD program (Federico II University of Naples)
- Bayer
- Jansen
- AstraZeneca
- Biosensors
- Medicines Company
- Bayer Health Care
- Biotronik
- Eli Lilly/DSI
- BMS
- Astra Zeneca
- OrbusNeich
- CSL Behring
Aspirin represents the sine qua non for antiplatelet pharmacotherapy in patients with cardiovascular diseases because of its well-established role in secondary prevention and its widespread availability and affordability. Historical studies, conducted in an era that bears little resemblance to contemporary clinical practice, demonstrated large reductions in thrombotic risk when aspirin was compared with placebo, thus forming the evidence base promulgated in practice guidelines and recommendations. P2Y(12) inhibitors have mostly been studied in addition to aspirin; dual-antiplatelet therapy proved superiority compared with aspirin monotherapy for the prevention of ischemic events, despite increased bleeding risks. An alternative approach currently under investigation includes evaluation of single-antiplatelet therapy with P2Y(12) inhibitors alone versus dual-antiplatelet therapy after acute coronary syndromes or coronary stent implantation. As the availability of more effective antiplatelet agents increases, it is time to revisit the existing and long-standing paradigm supporting aspirin use for secondary prevention of atherothrombotic events. Ongoing trials will provide new evidence whether the less-is-more strategy is justified.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据